Clinical trial
An Open-Label Feasibility/Pilot Study With [123I]-IBZM SPECT (DOPA-SYN)
NCT00200447 · Molecular NeuroImaging, Other · Completed
Key facts
| NCT number | NCT00200447 |
|---|---|
| Title | An Open-Label Feasibility/Pilot Study With [123I]-IBZM SPECT (DOPA-SYN) |
| Official title | Assessment of Carbidopa/l-Dopa and Carbidopa/l Dopa/Entacapone on Synaptic Dopamine in Parkinson's Patients: An Open-Label Feasibility/Pilot Study With [123I]-IBZM SPECT (DOPA-SYN) |
| Lead sponsor | Molecular NeuroImaging, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Parkinson's Disease |
| Intervention type | Drug, Procedure |
| Interventions | carbidopa/l-dopa, carbidopa/l-dopa/entacapone, Stalevo, [123I]-IBZM imaging |
| Enrollment | 3 |
| Start date | Mar 1, 2004 |
| Primary completion | Sep 1, 2004 |
| Completion | Sep 1, 2004 |
| First posted | Sep 20, 2005 |
| Last update posted | Jan 21, 2008 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: